Extracellular matrix Basic and translational science: Highlights of the congress

Similar documents
Inflammation in heart failure: biomarker, bystander or mediator

Mimecan and cardiac extracellular matrix integrity Lucas Van Aelst, MD Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium

The Cardiovascular System and Aging- Is it Built to Fail?

1. Cardiomyocytes and nonmyocyte. 2. Extracellular Matrix 3. Vessels שאלה 1. Pathobiology of Heart Failure Molecular and Cellular Mechanism

Uncovering the mechanisms of wound healing and fibrosis

Remodeling the failing heart: : the biology and future treatment options

Pathophysiology of heart failure with preserved ejection fraction. Extracellular matrix

Tissue repair. (3&4 of 4)

Risk Stratification in Heart Failure: The Role of Emerging Biomarkers

שינויים מולקולאריים ומבניים באי ספיקת לב אפשרויות לטיפול עתידני

Review. Myocardial Extracellular Matrix. An Ever-Changing and Diverse Entity

In Vivo Animal Models of Heart Disease. Why Animal Models of Disease? Timothy A Hacker, PhD Department of Medicine University of Wisconsin-Madison

Stratification of heart failure using biomarkers of myocardial fibrosis

Exploring the Reno-Cardiac Connection. Protect your kidneys save your heart

Biomarkers in cardiovascular disease. Felix J. Rogers, DO, FACOI April 29, 2018

Recovery of Myocardial Infarction via Unique Modulation of the Cardiac Microenvironment

Cardiovascular. Diseases. a simple and standardized kit qpcr analysis of circulating platelet-derived micrornas

2228 FEBS Journal 280 (2013) ª 2013 The Authors Journal compilation ª 2013 FEBS

The challenge of treating a stiff heart

Βασιλική Κατσή. Καρδιολόγος ΓNA Ιπποκράτειο

HYPERTENSION AND HEART FAILURE

Exercise in Adverse Cardiac Remodeling: of Mice and Men

The role of mirnas in cardiac hypertrophy

Mesenchymal Stem Cells to Repair Vascular Damage after Chemotherapy: Past, Present and Future

Integrative Physiology. Osteoglycin Prevents Cardiac Dilatation and Dysfunction After Myocardial Infarction Through Infarct Collagen Strengthening

Cell implantation after myocardial infarction: a 10 years experience from the ICREC laboratory

Diastolic Heart Failure

Inhibition of mir-29 protects against cardiac hypertrophy and fibrosis: new insight for the role of mir-29 in the heart

Cardioprotection by endogenous fibroblast growth factor 2 in cardiac ischemia-reperfusion injury in vivo

Utility of Circulating micrornas in Cardiovascular Disease

HFPEF Echo with Strain vs. MRI T1 Mapping

Healing & Repair. Tissue Regeneration

Healing and Repair. Dr. Nabila Hamdi MD, PhD

Review of Cardiac Imaging Modalities in the Renal Patient. George Youssef

Pro-enkephalin and Renal Disease. Alan H. Wu, Ph.D. University of California, San Francisco 12 th Annual UCSD Biomarkers of Cardiac Disease

ΒΙΟΔΕΙΚΤΕΣ ΣΤΗΝ ΚΑΡΔΙΑΚΗ ΑΝΕΠΑΡΚΕΙΑ. ΔΗΜΗΤΡΙΟΣ ΤΟΥΣΟΥΛΗΣ Καθηγητής Καρδιολογίας

In the treatment of partial and full-thickness chronic wounds TRANSFORM YOUR APPROACH TO HEALING: SIGNAL THE BODY, NOT THE WOUND DERMA

AN INNOVATIVE APPROCH TOWARDS IDENTIFICAION OF NOVEL THERAPEUTIC DRUG TARGETS TO IMPROVE THE MANAGEMENT OF HEART FAILURE

Assessment of Myocardial Collagen Content in a Novel Mouse Model Linked to Arrhythmogenic Right Ventricular Cardiomyopathy

When is strain assessment mandatory?

European Respiratory Society Annual Congress. Presented at: of new drugs for respiratory diseases. Barcelona, Spain, September 7-11, 2013 Page 1

Effects of Kidney Disease on Cardiovascular Morbidity and Mortality

Medical management of LV aneurysm and subsequent cardiac remodeling: is it enough? J. Parissis Attikon University Hospital Athens, Greece

microrna-21 contributes to kinase signalling in fibroblasts Thum et al (2008), Nature AOP December 1, 2008

Dilated cardiomyopathies. Gene mutations and beyond.

Growth Factors. BIT 230 Walsh Chapter 7

Reperfusion Injury: How Can We Reduce It?

DECLARATION OF CONFLICT OF INTEREST. No conflicts of interest

Cardiovascular Protection and the RAS

DOWNLOAD PDF CARDIAC REMODELING AND CELL DEATH IN HEART FAILURE

Journal Club Semmler Lorenz

J Jpn Coll Angiol, 2009, 49:

JASON ANTHONY LUCAS SUZANNE OPARIL (MENTOR) SUSAN BELLIS J. EDWIN BLALOCK YIU-FAI CHEN GILBERT PERRY JOANNE MURPHY-ULLRICH A DISSERTATION

Arteriosclerosis & Atherosclerosis

Angiotensin-Converting Enzyme-2 Overexpression Improves Left Ventricular Remodeling and Function in a Rat Model of Diabetic Cardiomyopathy

Tissue renewal and Repair. Nisamanee Charoenchon, PhD Department of Pathobiology, Faculty of Science

CNS Effects of Aldosterone :

Reprogramming through micrornas Stefanie Dimmeler

UvA-DARE (Digital Academic Repository) Genetic basis of hypertrophic cardiomyopathy Bos, J.M. Link to publication

Platelet Neutrophil crosstalk in thrombotic disorders Dimitrios A. Stakos

Understanding Root Cause: Pathogenesis of Hepatic Fibrosis

Declaration of conflict of interest. I have nothing to disclose.

Four Types of Vertebrate Tissue

Diabetes and the Heart

Myocardial infarction

Detection and Assessment of MI: Use of Imaging Methods. Robert O. Bonow, M.D.

Structural abnormalities of the heart and vascular system in CKD & Dialysis - Thick but weak

Η επίδραση της ηλικίας στη δομή και λειτουργία του μυοκαρδίου στους ηλικιωμένους

IL-17 in health and disease. March 2014 PSO13-C051n

Diagnosis is it really Heart Failure?

After myocardial infarction (MI), the left ventricle (LV)

Alterations in cardiomyocyte function during diastolic heart failure

Pathophysiology and Diagnosis of Heart Failure

Nox-Dependent Mechanisms of Cardiomyocyte Dysfunction in a Model of Pressure Overload

ROLE OF INFLAMMATION IN HYPERTENSION. Dr Barasa FA Physician Cardiologist Eldoret

Peter Walter, UCSF IRE1 Signaling Affects Cell Fate during the Unfolded Protein Response

Role of spironolactone in the treatment of heart failure with preserved ejection fraction

Left ventricular hypertrophy: why does it happen?

DECLARATION OF CONFLICT OF INTEREST

MicroRNA therapeutics for cardiovascular disease. Eva van Rooij, PhD Hubrecht Institute, KNAW and University Medical Center Utrecht, The Netherlands

Diastolic Function. Rick Nishimura Leighton Professor of CV Diseases Mayo Clinic No Disclosures

Connective Tissue Response in IBD

Postn MCM Smad2 fl/fl Postn MCM Smad3 fl/fl Postn MCM Smad2/3 fl/fl. Postn MCM. Tgfbr1/2 fl/fl TAC

New Frontiers in Atherosclerotic Disease and Myocardial Infarction: From local inflammation to systemic stem and progenitor cell reaction

Original Article Ca 2+ -calcineurin signaling is involved in norepinephrine-induced cardiac fibroblasts activation


Preserved EF with heart failure (HF pef) 50% 5 year survival. Both have type 2 diabetes Both have hypertension Both have normal ejection fractions

Atrial fibrillation and stroke. Isabelle C Van Gelder University Medical Center Groningen The Netherlands

Interrelationship Between Cardiac Hypertrophy, Heart Failure, and Chronic Kidney Disease: Endoplasmic Reticulum Stress As a Mediator of Pathogenesis

CD4+ Lymphocyte Regulation of Vascular and Cardiac Extracellular Matrix Structure and Function

Jaemin Lee, Ph.D. Department of New Biology Daegu Gyeongbuk Institute of Science and Technology (DGIST)

Yvan DEVAUX, PhD 45 years-old. Cardiovascular Research Unit Luxembourg Institute of Health (L.I.H.) 84 Val Fleuri L-1526 Luxembourg Luxembourg

Studies in the 1970s and 1980s from Zak and Nag defined. Review. Cardiac Fibroblast The Renaissance Cell

The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy

2016 Winter Meeting on Translational Heart Failure Research

Histopathology: Vascular pathology

EHRA/EUROPACE 2011 Madrid, Spain June

Diabetes influences cardiac extracellular matrix remodelling after myocardial infarction and subsequent development of cardiac dysfunction

microrna Therapeutics Heading Towards the Clinic

FOCUS ON CARDIOVASCULAR DISEASE

Transcription:

Extracellular matrix Basic and translational science: Highlights of the congress Stephane Heymans, Maastricht University Medical Centre, CARIM, Netherlands

Speaker

The extracellular matrix modulates cardiac cellular behaviour Proteoglycans (syndecans) Glycoproteins (thrombospondins) (Myo)fibroblast * Proliferation * Collagen production and cross-linking Exosomes/vesicles (micrornas) Cardiomyocyte * Hypertrophy * Survival Endothelial cell * Proliferation * Function Speaker Inflammatory cell * Invasion * Activation

Proteoglycans and glycoproteins protect against heart failure Thrombospondins, osteonectin (glycoproteins), syndecans (proteoglycans) Collagen production and maturation Myocyte survival Inflammation Δ Protect against cardiac systolic dysfunction Increase diastolic dysfunction Lynch JM, CellPapageorgiou A. CVR, 2012; Almen et al., JMCC, 2011; Schellings et al., J.Exp.Med, 2009; Swinnen et al., Circ, 2009; Herum KM, J Mol Cell Cardiol. 2013 Jan;54:73-81; Finsen AV, PLoS One. 2011;6(12):e28302; Vanhoutte D. Circulation. 2007 Jan 30;115(4):475-82; Schellings M, Hypertension. 2010 Feb;55(2):249-56 Speaker

MicroRNAs in matrix-exosomes alters cardiac fibrosis and hypertrophy Inflammatory cells Cardiomyocyte * Hypertrophy * Death/apoptosis Exosomes Fibroblast * Proliferation * Fibrosis S Heymans

Extracellular matrix modulates cardiac cellular behaviour Proteoglycans (syndecans) Glycoproteins (thrombospondins) (Myo)fibroblast * Proliferation * Collagen production and cross-linking Exosomes/vesicles (micrornas) Cardiomyocyte * Hypertrophy * Survival Endothelial cell * Proliferation * Function Speaker Inflammatory cell * Invasion * Activation

Syndecan-1 and 4 increase collagen production and myocyte hypertrophy Syndecan-4 stress Syndecan-1 and 4 are cardiac stress sensors Syndecan-1 TGFbeta pathway fibrosis Syndecan-4 calcineurin-nfat pathway fibrosis/hypertrophy Increases interstitial fibrosis Increased collagen production & cross-linking Myocardial stiffnessꜛ Stimulates myocyte hypertrophy P CnA NFAT Decreases cardiac inflammation NFAT Strand ME, FEBS J. 2013 May;280(10):2228-47; Herum KM, J Mol Cell Cardiol. 2013 Jan;54:73-81; Finsen AV, PLoS One. 2011;6(12):e28302; Vanhoutte D. Circulation. 2007 Jan 30;115(4):475-82; Schellings M, Hypertension. 2010 Feb;55(2):249-56 Geir Christensen, Vanhoutte and Kate Herum

Syndecan-4 affects myocardial stiffness in the pressure-overloaded heart Syndecan-4 KO mice & pressure-overload No titin changes Reduced total collagen Improved diastolic function Syndecan-1 KO mice & pressure-overload Reduced total collagen Improved diastolic function >< After MI: increased infarct rupture and dilatation INCREASED SYND1 and SYND4: DIASTOLIC DYSFUNCTION POST-INFARCT FAILURE Herum KM, J Mol Cell Cardiol. 2013 Jan;54:73-81; Finsen AV, PLoS One. 2011;6(12):e28302; Vanhoutte D. Circulation. 2007 Jan 30;115(4):475-82; Schellings M, Hypertension. 2010 Feb;55(2):249-56 Kate M. Herum

The extracellular matrix modulates cardiac cellular behaviour Proteoglycans (syndecans) Glycoproteins (thrombospondins) (Myo)fibroblast * Proliferation * Collagen production and cross-linking Exosomes/vesicles (micrornas) Cardiomyocyte * Hypertrophy * Survival Endothelial cell * Proliferation * Function Speaker Inflammatory cell * Invasion * Activation

Thrombospondins stimulate myocyte surival and affects cardiac fibrosis Thrombospondin-1, -2 and 4 are cardiac stress responders TSP-1 TGFbeta TSP-2 MMPs; CD47; NOS (matrix) TSP-4 endoplasmatic reticulum protective response (cardiomyocyte) Thrombospondin-2 Collagen maturation improved Inflammation reduced Cardiomyocyte survival Thrombospondin-4 Cardiomyocyte survival protective ER response Prevents adverse cardiomyocyte hypertrophy ER/SR Increased TSP-1, -2 and -4: BiP PROTECTIVE AGAINST HYPERTENSIVE HEART DISEASE (-1, -2 and -4) PREVENTS INFARCT RUPTURE AND DILATATION (-1 and -2) BiP BiP BiP Thbs4 PERK eif2 -Phos eif 2 Translation selective ATF4 Translation inhibition Translation IRE1 XBP1 XBP1 mrna processing protease Golgi ATF6 ATF6 BiP Thbs4 Nucleus Site 1 protease Lynch JM, Cell. 2012; 149(6):1257-68; Frolova EJ, FASEB J. 2012 Jun;26(6):2363-73. Cingolani, Circ Res. 2011 Dec 9;109(12):1410; Frolova EG, FASEB J. 2012 Jun;26(6):2363 Papageorgiou A. CVR, 2012; Almen et al., JMCC, 2011; Swinnen et al., Circ, 2009 Xia J, Hypertension. 2011 Nov;58(5):902-11 J Molketin and A Papageorgiou

Proteomics for discovery Speaker

Extracellular Matrix Remodelling Proteomics as an integrated read-out of pathophysiology Protein analysis without the constraints of antibodies Improvement over previous studies that simply evaluated the total concentration of single proteins (i.e., collagen) Often without consideration of type (e.g., type I vs III vs IV) or quality (full-length collagen vs partially degraded) Porcine model of ischemia/reperfusion injury and validated in human Liquid chromatography tandem mass spectrometry ECM Imaging Barallobre-Barreiro J, M Circulation. Mayr 2012 Feb 14;125(6):789

New matrix targets discovered Cartilage intermediate layer protein 1, Matrilin-4, Extracellular adipocyte enhancer binding protein 1, Asporin Prolargin Proteoglycans (syndecans) Glycoproteins (thrombospondins) Barallobre-Barreiro J, Circulation. 2012 Feb 14;125(6):789 Speaker

Extracellular Matrix Degradation: degradome Proteomics enhances degradome resolution Discovery pipeline for biomarkers and imaging targets Identify isoform-specific cleavage sites of matrix metalloproteinases Cleavage peptides may harbor as-yet undiscovered bioactive properties Stegemann C, Circ Cardiovasc Genet. 2013 Feb;6(1):106

The extracellular matrix modulates cardiac cellular behaviour Proteoglycans (syndecans) Glycoproteins (thrombospondins) (Myo)fibroblast * Proliferation * Collagen production and cross-linking Exosomes/vesicles (micrornas) Endothelial cell * Proliferation * Function Speaker Cardiomyocyte * Hypertrophy * Survival Inflammatory cell * Invasion * Activation

Exosome-derived microrna-21 increased cardiomyocyte hypertrophy and fibrosis Monocytes-MF MicroRNA-21 Fibroblast activation and fibrosis MicroRNA-21 * Cardiomyocyte Hypertrophy Claudia Bang & Shashi Kumar Gupta

Sirius Red H&E MHC-miR-199b NFAT : -exaggerated hypertrophy -increased fibrosis Syndecan-4 Myocyte hypertrophy Increased collagen Burcu Duygu

The extracellular matrix modulates cardiac cellular behaviour Proteoglycans (syndecans) Glycoproteins (thrombospondins) Exosomes/vesicles (micrornas) S Heymans

Increased synd-1 and -4 causes diastolic dysfunction but prevent infarct dilatation Syndecan-1 and 4 Collagen production (TGF & NFAT) Myocyte hypertrophy (NFAT) Inflammation Less infarct rupture & dilatation Diastolic dysfunction S Heymans

Thrombospondings protect against diastolic and systolic heart failure Thrombospondins Collagen maturation (TSP-1 & 2) Myocyte survival (TSP-2 & 4) Inflammation (TSP-2 & 4) Protect against systolic heart failure S Heymans

MicroRNAs in matrix-exosomes alters cardiac fibrosis and hypertrophy Inflammatory cells MicroRNA-199b Cardiomyocyte * Hypertrophy MicroRNA-(21 (*) ) Fibroblast * Collagen production SS Heymanspeaker